Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2009
Business Overview: Myriad is a leading healthcare company focused on molecular diagnostic products for predictive, personalized, and prognostic medicine. The company markets seven commercial products, primarily through a U.S. sales force, with BRACAnalysis accounting for the majority of revenues.
Material Corporate Event: On June 30, 2009, Myriad completed the spin-off of its research and drug development businesses into a new independent public company, Myriad Pharmaceuticals, Inc. (MPI). MPI was distributed to Myriad stockholders as a tax-free dividend. Results from the former drug development business are reported as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Fiscal Year 2009 | Fiscal Year 2008 |
|---|---|---|
| Molecular Diagnostic Revenue | $326.5 | $222.9 |
| Net Income (Total) | $84.6 | $47.8 |
| Income from Continuing Operations | $136.3 | $74.4 |
| Loss from Discontinued Operations | ($51.6) | ($26.5) |
| Operating Income (Continuing) | $126.5 | $61.6 |
| Gross Margin (Continuing) | 87% | 85% |
| Cash, Cash Equivalents & Marketable Securities | $392.2 | $420.1 |
| Net Cash Provided by Operating Activities | $84.0 | $103.7 |
| Accumulated Deficit | ($119.9) | ($204.6) |
Material Changes vs. Prior Period
- Revenue Growth: Molecular diagnostic revenue increased 47% year-over-year, driven by increased testing volume and expanded sales/marketing efforts. However, management noted a dampening effect on growth in the fourth quarter due to the economic recession and loss of insurance coverage.
- Profitability: Net income from continuing operations increased significantly ($136.3M vs $74.4M), aided by a 2% increase in gross margins to 87% due to operational efficiencies. Total net income was impacted by a $51.6M loss from discontinued operations (MPI), compared to a $26.5M loss in the prior year.
- Expense Trends: Selling, general, and administrative (SG&A) expenses rose 26% to $138.9M, primarily due to sales force expansion, marketing campaigns, and a $4.6M increase in bad debt expense. Research and development expenses for continuing operations decreased slightly to $17.9M.
- Liquidity: Total cash and marketable securities decreased by $27.9M to $392.2M. This reduction was primarily due to the transfer of $188.0M in cash and securities to MPI during the spin-off, partially offset by strong operating cash flow.
- Investment Impairment: The company recorded a $2.0M other-than-temporary impairment loss on marketable securities related to Lehman Brothers Holdings, Inc.
Guidance, Outlook, and Risks
- Outlook: Management expects existing capital resources and cash generated from operations to fund current operations for at least the next two years. The company plans to continue expanding its sales force and market penetration in the U.S. and internationally.
- Economic Risks: The company highlighted risks associated with the economic recession, including unemployment, loss of employer-sponsored insurance, and reduced doctor visits, which could dampen revenue growth.
- Regulatory Risks: Significant uncertainty exists regarding FDA regulation of laboratory-developed tests (IVDMIAs). While the FDA has historically exercised enforcement discretion, new guidance could require pre-market review, potentially halting sales pending clearance.
- Intellectual Property: The company faces ongoing litigation regarding the validity of patents related to the BRCA1 and BRCA2 genes (Association for Molecular Pathology v. Myriad). A ruling invalidating these patents could materially harm the business.
- Reimbursement: Revenue depends heavily on third-party payor reimbursement. Changes in healthcare payment systems or denial of coverage could adversely affect profitability.
Key Facts for Investor Verification
- Spin-off Completion: Verify the independence of Myriad Pharmaceuticals, Inc. (MPI) and confirm that Myriad Genetics retains no ownership interest in MPI post-June 30, 2009.
- Patent Litigation Status: Monitor the status of the lawsuit filed by the Association for Molecular Pathology challenging the validity of BRCA gene patents, which are central to the company's primary revenue stream.
- Reimbursement Trends: Assess the impact of the economic downturn on insurance coverage and reimbursement rates for molecular diagnostic tests.
- Deferred Tax Assets: Note the full valuation allowance of approximately $110.7M against deferred tax assets; future profitability could trigger a reversal of this allowance, impacting future tax provisions.
- Single Facility Risk: Confirm the operational resilience of the single CLIA-approved laboratory facility in Salt Lake City, which processes all molecular diagnostic tests.